Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases

British Journal of Cancer

Volumn 78, Issue 8, 1998, Pages 1058-1060

  Fordy, C ^a   Glover, C ^a   Davies, M M ^a   Allen Mersh, T G ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal liver metastases; Fluorouracil resistance; Hepatic arterial floxuridine

Indexed keywords

FLOXURIDINE; PYRIMIDINE ANTAGONIST;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; MALE; PRIORITY JOURNAL;

EID: 0031687077     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.627     Document Type: Article

References (28)

1. Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903
2. Allen-Mersh TG, Niedzwiecki D, Shurgot B, Kemeny N and Daly JM (1987) Significance of a fall in the serum CEA following chemotherapy for disseminated colorectal cancer. Gut 28: 1625-1629
3. Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J (1994) Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260
4. Bergner M, Bobbitt RA, Carter WB and Gilson BS (1981) The Sickness Impact File: development and final revision of a health status measure. Medcare 19: 787-905
5. Burke D, Earlam S, Fordy C and Allen-Mersh TG (1995) Effect of aberrant hepatic arterial anatomy on tumour response to regional floxuridine infusion for colorectal liver metastases. Br J Surg 82: 1098-1100
6. Burke D, Fordy C, Earlam S and Allen-Mersh TG (1997) Hepatic arterial cannulation for regional chemotherapy is safe in patients with a liver metastasis volume of less than 1 litre. Br J Cancer 75: 1213-1216
7. Buroker TR, O'Connell MJ, Wieand S, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG and Gesme DH (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20
8. DeHaes IC, Van Knippenberg FC and Neijt JP (1990). Measuring psychological and physical distress in cancer patients; structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62: 1034-1038
9. Dworkin MJ, Burke D, Earlam S, Fordy C and Allen-Mersh TG (1995) Measurement of response to treatment in colorectal liver metastases. Br J Cancer 71: 873-876
10. Earlam S, Glover G, Fordy C, Burke D and Allen-Mersh TG (1996) Relation between tumour size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 14: 171-175
11. Earlam S, Glover C, Davies M, Fordy C and Allen-Mersh TG (1997) Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 15: 2022-2029
12. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G and Frei III E (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluouracil. Cancer Res 38: 3784-3792
13. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A and Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89-94
14. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, Acord P and Lewis BJ (1989). A randomised trial of continuous intravenous versus intraarterial floxuridine in patients with colorectal cancer metastatic to the liver. J Clin Oncol 7: 1646-1653
15. Jenh CH, Geyer PK, Baskin F and Johnson LF (1985) Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol Pharmacol 28: 80-85
16. Kemeny N, Daly J, Reichman B, Geller N, Botet J and Oderman P (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Int Med 107: 459-465
17. Kemeny N, Seller K, Niedzwiecki D, Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P and Murray P (1992) A randomised trial of intrahepatic infusion of FUDR with dexamethasone versus FUDR alone in the treatment of metastatic colorectal cancer. Cancer 69: 327-334
18. Kemeny N, Lokich JJ, Anderson N and Ahloren JD (1993) Recent advances in the treatment of advanced colorectal cancer. Cancer 71: 9-18
19. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismuth H, Jasmin C and Misset JL (1994) Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomised multi-institutional trial. J Natl Cancer Inst 86: 1608-1617
20. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 10: 904-911
21. O'Connell M (1989) A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026-1030
22. Patt YZ, Hoque A, Lozano R, Pazdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M and Jones DV (1997) Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human inferferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol 15: 1432-1438
23. Piedbois P, Buyse M, Kemeny N, Rougier P, Carlson R, Allen-Mersh TG, O'Connell M, Chang A, Sondak V, Kemeny M and Levi E (1996) Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-25
24. Rothenburg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt G, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ and Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135
25. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Yehou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P and Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260
26. Tournigand C, Louvet C, de Gramond A, Lucchi E, Seitz JF, Mal F, Raymond E, Cady J, Carola E and Krulik M (1997) Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Cancer 79: 1094-1099
27. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publications no. 48. WHO: Geneva
28. Zigmund AS and Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370